Search results
Moderna posts quarterly sales beat, smaller loss than expected
Reuters via Yahoo Finance· 19 hours ago(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 15 hours ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune· 8 hours agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company’s first quarter ...
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
AOL· 11 hours agoThe dark days of the pandemic are finally in the past for most of us—and that seems to be reflected in the earnings for Moderna, whose revenue is dependent on sales of its ...
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch | Invezz
Invezz· 18 hours agoModerna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year,...
Moderna Quarterly Sales Beat Expectations but Plummet From Previous Year
US News & World Report· 19 hours agoThe Cambridge, Massachusetts-based drugmaker reaffirmed that it expects to receive approval from regulators for its respiratory syncytial virus (RSV) vaccine in time for it to be included in ...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 19 hours agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
Moderna quarterly sales beat expectations but plummet from previous year
Reuters via Yahoo Finance· 19 hours agoModerna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was ...
Should You Buy Moderna Before May 12?
Motley Fool via Yahoo Finance· 7 days agoThe Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends GSK and Moderna. The Motley Fool has a disclosure policy. Should You...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 2 days agoIt will be important to watch how Pfizer stock performs as the company shores up its pipeline and...
